Transcat Inc. Soars to New Heights: Q2 2027 Earnings Exceed Expectations
Transcat Inc., a leading provider of calibration services and medical equipment solutions, has once again demonstrated its commitment to delivering exceptional financial performance. The company's recent Q2 2027 earnings call highlighted impressive growth across various business pillars, solidifying its position as a leader in the industry.
In a conference call on November 3rd, 2026, Transcat's President and CEO, Jaime Irick, reported strong results for the fiscal second quarter of 2027. The company's consolidated revenue increased by 18% to $97.1 million, driven by double-digit growth in both segments. This significant jump in revenue was led by a 31% surge in service gross profit, underscoring Transcat's ability to capitalize on demand in highly regulated end markets.
Jaime Irick highlighted the company's success in gaining share in calibration services through organic growth, disciplined mergers and acquisitions (M&A), and a more productive sales organization. This strategy has further widened its competitive moat, making it an even more formidable player in the industry.
The fiscal second quarter marked another sequential quarter of strong financial performance for Transcat, with adjusted EBITDA growing 23% and adjusted EBITDA margins expanding by 70 basis points to 15.4%. This impressive growth was driven by revenue momentum combined with productivity gains, demonstrating the company's ability to optimize its business processes.
Transcat's service results were particularly noteworthy, with service revenue increasing by 23% in the fiscal second quarter. Service organic revenue grew 16%, marking the company's 70th consecutive quarter of year-over-year growth. This remarkable streak is a testament to Transcat's commitment to delivering exceptional value to its customers.
The acquisition of Southeastern Biomedical Associates in August further solidified Transcat's position as a leader in regulated, high-cost-of-failure end markets. Southeastern is known for its quality and customer-first approach in supporting hospital networks across the southeastern United States, aligning perfectly with Transcat's strategic objectives.
In conclusion, Transcat Inc.'s Q2 2027 earnings call provided valuable insights into the company's continued success. With a strong track record of growth, expanded margins, and strategic acquisitions, Transcat is poised to maintain its position as a leader in the industry. As the company continues to execute its vision for operational excellence, investors can expect further impressive results from this exceptional performer.
